Evidence map›Paper›PMID 41703144›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Re-evaluation of current status and needs of long-term follow-up clinics for hematopoietic cell transplant survivors: results of a nationwide survey in Japan.

Saiko Kurosawa, Ayako Mori, Hideki Goto, Minami Yamada-Fujiwara, Noriko Doki, Yuki Asano-Mori, Tatsunori Goto, Tatsuya Imi, Hirohisa Nakamae, Keisuke Seike and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Saiko KurosawaDepartment of Oncology, Ina Central Hospital, 1313-1 Koshiro-Kubo, Ina, Nagano, 396-8555, Japan. skurosaw@inahp.jp.
Ayako MoriNursing Division, National Cancer Center Hospital, Tokyo, Japan.
Hideki GotoDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Minami Yamada-FujiwaraDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Yuki Asano-MoriDepartment of Transfusion Medicine and Cell Therapy, Toranomon Hospital, Tokyo, Japan.
Tatsunori GotoDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Aichi, Japan.
Tatsuya ImiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University, Osaka, Japan.
Keisuke SeikeDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Yuichiro NawaDivision of Hematology, Ehime Prefectural Central Hospital, Ehime, Japan.
Yasuo MoriHematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Satoru HamadaDepartment of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
Shuichi OzonoDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan.
Hiroshi OkamuraDepartment of Hematology, Osaka Metropolitan University, Osaka, Japan.
Akinori NishikawaDepartment of Hematology/Oncology, Wakayama Medical University Hospital, Wakayama, Japan.
Hisayo DoiNursing Division, Kobe University Hospital, Kobe, Japan.
Tomoko FukuchiNursing Division, Osaka Women's and Children's Hospital, Osaka, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLong-term follow-up (LTFU) outpatient clinics play a primary role in screening, preventing, and addressing late effects after hematopoietic cell transplantation (HCT). Following the 2018 nationwide survey, which led to the development of standardized nationwide tools to deliver information to HCT survivors, we re-evaluated changes in the current status of LTFU clinics.

methodsWe targeted 267 HCT centers certified by the Japanese society for transplantation and cellular therapy. Several questionnaire categories were retained from the 2018 survey to compare results (e.g., LTFU clinic establishment and institutional practices for late-effect screening).

resultsThe response rate was high in both adult (90%) and pediatric HCT centers (88%), and the establishment rate of post-HCT LTFU clinics increased to 82% (adult, 90%; pediatric, 64%). Pediatric centers were more likely to continue follow-up of patients who received HCT beyond 5 years post-HCT. Regarding transitional medical care for long-term survivors at non-HCT institutions, only a few HCT centers conducted routine transitions to specific referral facilities. We observed significant changes in recommendations for secondary cancer screenings compared to 2018, with a substantial decrease in the proportions of "not routinely included as a screening issue."

conclusionsIn the future, it is essential to create a sustainable follow-up system, establish networks with non-HCT facilities, and educate patients to encourage behavioral changes for lifelong health screenings.

Indexed as

Ambulatory Care FacilitiesHematopoietic Stem Cell TransplantationAdultFollow-Up StudiesHumansJapanSurveys and QuestionnairesSurvivorsTime FactorsAllogeneic hematopoietic cell transplantationLate effectsLong-term follow-upSecondary cancer screeningTransition

Identifiers

PMID41703144

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.